Ann Surg Treat Res.  2014 Jul;87(1):5-8. 10.4174/astr.2014.87.1.5.

Prognosis of early mucinous gastric carcinoma

• Ryu SY
• Kim HG
• Lee JH
• Kim DY

• KMID: 1804092
• DOI: http://doi.org/10.4174/astr.2014.87.1.5

Abstract

PURPOSE
Little is known about the clinicopathological features of early mucinous gastric carcinoma (MGC). The purpose of this study was to compare the clinicopathological features and prognosis between patients with early MGC and those with early nonmucinous gastric carcinoma (NMGC).
METHODS
We reviewed the records of 2,732 patients diagnosed with gastric carcinoma who were treated surgically. There were 14 patients (0.5%) with early MGC and 958 with early NMGC.
RESULTS
Early MGC patients had a higher prevalence of elevated type (71.4%) compared with early NMGC patients (29.5%). More early MGC patients had submucosal carcinoma, compared with early NMGC patients (78.6% vs. 64.1%). The overall 5-year survival of the patients with early MGC was 97.2% as compared with 92.7% for the patients with early NMGC (P < 0.01). The statistically significant prognostic parameters influencing the 5-year survival rate according to Cox's proportional hazard regression model were: age (risk ratio, 2.22; 95% confidence interval [CI], 1.62-3.04; P < 0.01); sex (risk ratio, 1.97; 95% CI, 1.42-2.73; P < 0.01); and lymph node metastases (risk ratio, 1.88; 95% CI, 1.28-2.77; P < 0.01).
CONCLUSION
Patients with early MGC had a better prognosis than those with early NMGC. Mucinous histology itself appears not to be an independent prognostic factor. Therefore, early detection is important for improving the prognosis for patients with gastric carcinoma regardless of tumor histology.

Keyword

Gastric neoplasm; Mucinous; Prognosis; Tumor histology

MeSH Terms

Humans
Lymph Nodes
Mucins*
Neoplasm Metastasis
Prevalence
Prognosis*
Stomach Neoplasms
Survival Rate
Mucins

Figure

• 

  Fig. 1 Survival curves of early mucinous gastric carcinoma (MGC) and early nonmucinous gastric carcinoma (NMGC; 5-year survival rate: 97.2% vs. 92.7%, P = 0.001).

Reference

1. Adachi Y, Mori M, Kido A, Shimono R, Maehara Y, Sugimachi K. A clinicopathologic study of mucinous gastric carcinoma. Cancer. 1992; 69:866–871.

2. Wu CY, Yeh HZ, Shih RT, Chen GH. A clinicopathologic study of mucinous gastric carcinoma including multivariate analysis. Cancer. 1998; 83:1312–1318.

3. Kawamura H, Kondo Y, Osawa S, Nisida Y, Okada K, Isizu H, et al. A clinicopathologic study of mucinous adenocarcinoma of the stomach. Gastric Cancer. 2001; 4:83–86.

4. Kunisaki C, Akiyama H, Nomura M, Matsuda G, Otsuka Y, Ono HA, et al. Clinicopathologic characteristics and surgical outcomes of mucinous gastric carcinoma. Ann Surg Oncol. 2006; 13:836–842.

5. Hyung WJ, Noh SH, Shin DW, Yoo CH, Kim CB, Min JS, et al. Clinicopathologic characteristics of mucinous gastric adenocarcinoma. Yonsei Med J. 1999; 40:99–106.

6. Lim SW, Kim DY, Kim YJ, Kim SK. Clinicopathologic features of mucinous gastric carcinoma. Dig Surg. 2002; 19:286–290.

7. Yasuda K, Shiraishi N, Inomata M, Shiroshita H, Ishikawa K, Kitano S. Clinicopathologic characteristics of early-stage mucinous gastric carcinoma. J Clin Gastroenterol. 2004; 38:507–511.

8. Japanese Gastric Cancer Association. Japanese Classification of Gastric Carcinoma - 2nd English edition. Gastric Cancer. 1998; 1:10–24.

9. Davis GR. Neoplasms of the stomach. In : Sleisenger MH, Fordtrans JS, editors. Gastrointestinal disease. Philadelphia: Saunders;1993. p. 763–768.

10. Caruso RA. The histogenesis of mucinous adenocarcinoma of the stomach from observations in early gastric cancer. Ann Diagn Pathol. 1999; 3:160–164.

11. Zhang M, Zhu GY, Zhang HF, Gao HY, Han XF, Xue YW. Clinicopathologic characteristics and prognosis of mucinous gastric carcinoma. J Surg Oncol. 2010; 102:64–67.

12. Adachi Y, Yasuda K, Inomata M, Shiraishi N, Kitano S, Sugimachi K. Clinicopathologic study of early-stage mucinous gastric carcinoma. Cancer. 2001; 91:698–703.

13. Yin C, Li D, Sun Z, Zhang T, Xu Y, Wang Z, et al. Clinicopathologic features and prognosis analysis of mucinous gastric carcinoma. Med Oncol. 2012; 29:864–870.

14. Choi MG, Sung CO, Noh JH, Kim KM, Sohn TS, Kim S, et al. Mucinous gastric cancer presents with more advanced tumor stage and weaker β-catenin expression than nonmucinous cancer. Ann Surg Oncol. 2010; 17:3053–3058.

15. Ma J, De Boer WG, Nayman J. Intestinal mucinous substances in gastric intestinal metaplasia and carcinoma studied by immunofluorescence. Cancer. 1982; 49:1664–1667.

16. Kim JP. Results of surgery 6,589 gastric cancer patients indicating immunochemosurgery as being the best multimodality treatment for advanced gastric cancer. In : Nishi M, Ichikawa H, Nakajima T, Maruyama K, Tahara E, editors. Gastric cancer. Tokyo: Springer;1993. p. 358–377.